MCID: END032
MIFTS: 33

Endometrial Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Clear Cell Adenocarcinoma

MalaCards integrated aliases for Endometrial Clear Cell Adenocarcinoma:

Name: Endometrial Clear Cell Adenocarcinoma 12 15 17 70
Clear Cell Carcinoma of Endometrium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5299
NCIt 50 C8028
UMLS 70 C0279765

Summaries for Endometrial Clear Cell Adenocarcinoma

Disease Ontology : 12 An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm.

MalaCards based summary : Endometrial Clear Cell Adenocarcinoma, also known as clear cell carcinoma of endometrium, is related to endometrial cancer and endometrial adenocarcinoma. An important gene associated with Endometrial Clear Cell Adenocarcinoma is ANGPTL4 (Angiopoietin Like 4), and among its related pathways/superpathways are NRF2 pathway and HIF1Alpha Pathway. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, ovary and uterus.

Related Diseases for Endometrial Clear Cell Adenocarcinoma

Diseases related to Endometrial Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 endometrial cancer 10.1
2 endometrial adenocarcinoma 10.1
3 adenocarcinoma 10.1
4 clear cell adenocarcinoma 10.1
5 extracranial carotid artery aneurysm 10.1
6 fanconi syndrome 9.5 SLC2A6 CTSD

Graphical network of the top 20 diseases related to Endometrial Clear Cell Adenocarcinoma:



Diseases related to Endometrial Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Endometrial Clear Cell Adenocarcinoma

Drugs & Therapeutics for Endometrial Clear Cell Adenocarcinoma

Drugs for Endometrial Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
4
Pembrolizumab Approved Phase 3 1374853-91-4
5 Tubulin Modulators Phase 3
6 Antimitotic Agents Phase 3
7 Albumin-Bound Paclitaxel Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
10 Protein Kinase Inhibitors Phase 2
11 Pharmaceutical Solutions

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
2 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Unknown status NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
3 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
4 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
5 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
6 A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression Active, not recruiting NCT02059265 Phase 2 Dasatinib
7 Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
8 Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer Active, not recruiting NCT01737619 Indocyanine Green Solution

Search NIH Clinical Center for Endometrial Clear Cell Adenocarcinoma

Genetic Tests for Endometrial Clear Cell Adenocarcinoma

Anatomical Context for Endometrial Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Endometrial Clear Cell Adenocarcinoma:

40
Lymph Node, Ovary, Uterus

Publications for Endometrial Clear Cell Adenocarcinoma

Articles related to Endometrial Clear Cell Adenocarcinoma:

# Title Authors PMID Year
1
An Isolated Metastasis From Clear Cell Renal Cell Carcinoma to the Uterus: A Case Report and Review of Literature. 61
26630224 2016
2
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. 61
24817975 2014
3
Endometrial clear cell adenocarcinoma diagnosed by endometrial cytological examination: two cases report. 61
21319323 2011
4
Two kinds of endometrial neoplasia arising from different origins in the uterine corpus: comparison of p53 expression and sex steroid receptor status. 61
12206933 2002
5
[Phase I study of a combination chemotherapy of nedaplatin and cisplatin]. 61
10635306 1999
6
Late recurrence of a uterine clear cell adenocarcinoma confined to an endometrial polyp: case report. 61
10215432 1998
7
Characterization of a newly established human tumor cell line (TEN) from a patient with clear cell carcinoma of the uterine body and its sensitivity to anti-cancer agents. 61
9436040 1997
8
Clear cell carcinoma of endometrium. 61
462571 1979

Variations for Endometrial Clear Cell Adenocarcinoma

Cosmic variations for Endometrial Clear Cell Adenocarcinoma:

9 (show top 50) (show all 1551)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87278348 ZFHX3 endometrium,NS,carcinoma,clear cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 3
2 COSM149281700 ZFHX3 endometrium,NS,carcinoma,clear cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 3
3 COSM102027267 ZFHX3 endometrium,NS,carcinoma,clear cell carcinoma c.5875G>A p.E1959K 16:72794065-72794065 3
4 COSM127993118 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
5 COSM85231580 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
6 COSM90942592 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
7 COSM143036126 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
8 COSM145022824 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
9 COSM133267215 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
10 COSM126967951 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.-84C>G p.? 11:102114273-102114273 3
11 COSM128446746 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 3
12 COSM104889254 XPO1 endometrium,NS,carcinoma,clear cell carcinoma c.1888G>A p.V630I 2:61490776-61490776 3
13 COSM101982273 XPO1 endometrium,NS,carcinoma,clear cell carcinoma c.1888G>A p.V630I 2:61490776-61490776 3
14 COSM104241825 XPO1 endometrium,NS,carcinoma,clear cell carcinoma c.1888G>A p.V630I 2:61490776-61490776 3
15 COSM131773760 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.-248T>A p.? 1:117170166-117170166 3
16 COSM108959432 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.38T>A p.I13N 1:117170166-117170166 3
17 COSM95872718 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.47T>A p.I16N 1:117170166-117170166 3
18 COSM96870610 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.38T>A p.I13N 1:117170166-117170166 3
19 COSM91947019 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.38T>A p.I13N 1:117170166-117170166 3
20 COSM88793278 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
21 COSM97137412 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
22 COSM146193551 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
23 COSM128341153 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
24 COSM143165850 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
25 COSM118538076 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
26 COSM147029139 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
27 COSM97164631 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
28 COSM106393589 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
29 COSM97204672 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
30 COSM128142401 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
31 COSM128631961 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
32 COSM127347554 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
33 COSM126889852 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
34 COSM144538083 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
35 COSM146257698 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
36 COSM142534595 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
37 COSM97172643 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
38 COSM112508849 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
39 COSM105691292 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
40 COSM142955207 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
41 COSM128499899 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.7T>C p.F3L 6:43771253-43771253 3
42 COSM107299029 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 3
43 COSM90423379 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.1790A>G p.H597R 16:2070529-2070529 3
44 COSM110110172 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3574+693C>A p.? 16:2082491-2082491 3
45 COSM90410474 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3814+693C>A p.? 16:2082491-2082491 3
46 COSM151751093 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3741C>A p.S1247R 16:2082491-2082491 3
47 COSM101198681 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.1643A>G p.H548R 16:2070529-2070529 3
48 COSM102625510 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3682+693C>A p.? 16:2082491-2082491 3
49 COSM136636080 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.1823A>G p.H608R 16:2070529-2070529 3
50 COSM150361875 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3685+693C>A p.? 16:2082491-2082491 3

Expression for Endometrial Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Clear Cell Adenocarcinoma.

Pathways for Endometrial Clear Cell Adenocarcinoma

Pathways related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.96 SLC2A8 SLC2A6 SLC2A12
2 10.69 SLC2A6 SLC2A12

GO Terms for Endometrial Clear Cell Adenocarcinoma

Cellular components related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosomal membrane GO:0005765 8.8 SLC2A8 SLC2A6 CTSD

Biological processes related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.54 SLC2A8 SLC2A6 SLC2A12
2 response to hypoxia GO:0001666 9.4 SLC2A8 ANGPTL4
3 carbohydrate transport GO:0008643 9.33 SLC2A8 SLC2A6 SLC2A12
4 dehydroascorbic acid transport GO:0070837 9.32 SLC2A8 SLC2A6
5 fructose transmembrane transport GO:0015755 9.26 SLC2A8 SLC2A6
6 glucose transmembrane transport GO:1904659 9.13 SLC2A8 SLC2A6 SLC2A12
7 hexose transmembrane transport GO:0008645 8.8 SLC2A8 SLC2A6 SLC2A12

Molecular functions related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.43 SLC2A8 SLC2A6 SLC2A12
2 glucose transmembrane transporter activity GO:0005355 9.16 SLC2A8 SLC2A6
3 dehydroascorbic acid transmembrane transporter activity GO:0033300 8.96 SLC2A8 SLC2A6
4 fructose transmembrane transporter activity GO:0005353 8.62 SLC2A8 SLC2A6

Sources for Endometrial Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....